Seres therapeutics reports inducement grants under nasdaq listing rule 5635(c)(4)

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb) (“seres” or the “company”), a leading microbiome therapeutics company, today announced that on june 7, 2023, the compensation and talent committee of seres' board of directors granted inducement equity grants covering an aggregate of 19,400 shares of its common stock to six new employees, consisting of stock options to purchase an aggregate of 9,700 shares of common stock and restricted stock units (“rsus”), covering an.
MCRB Ratings Summary
MCRB Quant Ranking